Warren Hazelton

Warren Hazelton is a Scientist I at T-Therapeutics Ltd, specializing in preclinical development since November 2023. Prior experience includes a role as a Postdoctoral Researcher at University College London from September 2018 to November 2023, where Warren advanced a multi-antigen targeting CAR T-cell therapy for acute myeloid leukaemia (AML) leading to successful funding applications totaling £3M. Warren's academic background includes a Doctoral study focused on the development of multi-antigen targeting chimeric antigens for AML treatment. Previous positions include Research Associate at Autolus Ltd., Research Assistant at University College London, and Industrial Placement Student at GSK, where expertise in synthetic biology, molecular biology, and tissue culture techniques was developed. Warren holds an MBiolSci degree in Biochemistry and Microbiology from The University of Sheffield.